15 completed, 7 unknown, 4 terminated, 3 not yet recruiting. 35 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 35 | Completed 15, Unknown 7, Terminated 4, Not yet recruiting 3, Active not recruiting 2, Recruiting 2, Withdrawn 2 |
Follow Ovarian Neoplasms: new trials by email Literature Review of Ovarian Neoplasms trials Research Report on Ovarian Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery Indocyanine Green, Near-Infrared Fluorescence Imaging System - Gynecologic Cancers, Ovarian Cancer | Phase 4 | Not yet recruiting | Istanbul University | 50 | 2027-06-01 | 2026-11-18 |
| CYTALUX Dose Extension Study CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer | Phase 4 | Not yet recruiting | On Target Laboratories, LLC | 106 | 2026-11-15 | 2026-11-09 |
| Study Evaluating Safety, Tolerability, and Metabolism of Niraparib Niraparib - Ovarian Cancer | Phase 4 | Recruiting | University of Miami | 70 | 2026-07-28 | 2026-08-05 |
| A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer Niraparib - Ovarian Neoplasms | Phase 4 | Not yet recruiting | GlaxoSmithKline | 67 | 2025-04-22 | 2025-03-21 |
| OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Olaparib, Lenvatinib, Sunitinib - Renal Cell Carcinoma, Ovarian Carcinoma | Phase 4 | Unknown | University Medical Center Groningen | 30 | 2024-05-01 | 2023-11-29 |
| First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients Olaparib, Bevacizumab - Carcinoma, Ovarian Epithelial | Phase 4 | Active not recruiting | Mario Negri Institute for Pharmacological Research | 190 | 2023-09-15 | 2026-06-25 |
| The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action Propofol, Sevoflurane - Lung Cancer, Brain Tumor | Phase 4 | Unknown | Kaohsiung Medical University Chung-Ho Memorial Hospital | 1316 | 2023-05-23 | 2023-09-28 |
| Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) Propofol 1%, Sevoflurane/Ultane - Ovarian Cancer | Phase 4 | Recruiting | Kaohsiung Medical University Chung-Ho Memorial Hospital | 416 | 2022-11-23 | 2023-05-30 |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer Niraparib - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 4 | Unknown | Seoul National University Hospital | 102 | 2022-01-01 | 2022-01-26 |
| NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. Pharmacokinetics, Dosage of Niraparib - Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer | Phase 4 | Terminated | Hospices Civils de Lyon | 12 | 2021-05-05 | 2025-05-22 |
| Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Aspirin - Venous Thromboembolism, Ovarian Cancer | Phase 4 | Completed | Duke University | 19 | 2020-08-08 | 2022-09-26 |
| A Study of Serum Folate Levels in Patients Treated With Olaparib Folic Acid Tablet - Ovarian Cancer, Breast Cancer | Phase 4 | Completed | Rush University Medical Center | 10 | 2020-07-21 | 2026-03-04 |
| Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer Olaparib - Ovarian Cancer, Breast Cancer | Phase 4 | Completed | AstraZeneca | 202 | 2020-05-25 | 2025-03-10 |
| NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Niraparib - Ovarian Cancer | Phase 4 | Completed | ARCAGY/ GINECO GROUP | 141 | 2019-04-03 | 2024-12-13 |
| Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer pegylated liposomal doxorubicin, paclitaxel, Carboplatin - Efficacy and Safety | Phase 4 | Unknown | Women's Hospital School Of Medicine Zhejiang University | 396 | 2019-03-19 | 2022-07-18 |
| An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Bevacizumab - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 4 | Completed | Hoffmann-La Roche | 100 | 2018-12-05 | 2025-06-26 |
| Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Fluciclovine F18 - Cervical Cancer, Endometrial Cancer | Phase 4 | Unknown | Bital Savir-Baruch | 30 | 2018-11-14 | 2020-02-28 |
| NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma BRCA testing - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 4 | Active not recruiting | European Institute of Oncology | 323 | 2018-06-12 | 2025-05-15 |
| Diaphragmatic Resection And Gynecological Ovarian Neoplasm thoracic Drain Tube 24 Fr. - Ovarian Cancer | Phase 4 | Completed | Catholic University of the Sacred Heart | 88 | 2018-03-20 | 2020-05-22 |
| Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations apatinib - Stage IV Cancer | Phase 4 | Unknown | Sun Yat-sen University | 217 | 2018-02-26 | 2020-05-12 |
Showing 20 of 35. Sign in to see all of them.
Breast Neoplasms (8) · Carcinoma, Ovarian Epithelial (4) · Endometrial Neoplasms (4) · Lung Neoplasms (4) · Uterine Cervical Neoplasms (4) · Brain Neoplasms (2) · Fallopian Tube Neoplasms (2) · Neoplasms (2) · Recurrence (2) · Uterine Neoplasms (2) · Anastomotic Leak (1) · Anemia (1) · Blood Loss, Surgical (1) · Carcinoma, Non-Small-Cell Lung (1)
Adnexal Diseases (35) · Endocrine Gland Neoplasms (35) · Endocrine System Diseases (35) · Female Urogenital Diseases (35) · Female Urogenital Diseases and Pregnancy Complications (35) · Genital Diseases (35) · Genital Diseases, Female (35) · Genital Neoplasms, Female (35) · Gonadal Disorders (35) · Neoplasms by Site (35) · Ovarian Diseases (35) · Urogenital Diseases (35) · Urogenital Neoplasms (35) · Neoplasms (33) · Breast Diseases (8)
niraparib (4) · Bevacizumab (3) · Carboplatin (3) · olaparib (3) · Paclitaxel (2) · Propofol (2) · Saline Solution (2) · Sevoflurane (2) · apatinib (2) · liposomal doxorubicin (2) · Anesthesia, Inhalation (1) · Aprepitant (1) · Aspirin (1) · Dexamethasone (1) · Folic Acid (1)
Kaohsiung Medical University Chung-Ho Memorial Hospital (2) · ARCAGY/ GINECO GROUP (1) · Amgen (1) · AstraZeneca (1) · Bital Savir-Baruch (1) · Catholic University of the Sacred Heart (1) · Dartmouth-Hitchcock Medical Center (1) · Duke University (1) · Eli Lilly and Company (1) · European Institute of Oncology (1) · GlaxoSmithKline (1) · Gynecologic Oncology Associates (1) · Hoffmann-La Roche (1) · Hospices Civils de Lyon (1) · Istanbul University (1)
United States (9) · China (4) · Italy (4) · France (2) · India (2) · Netherlands (2) · Taiwan (2) · Austria (1) · Canada (1) · Germany (1) · Nigeria (1) · Sweden (1) · Turkey (Türkiye) (1)
Zhi-Fu Wu (2) · Aleena Banerji, MD (1) · Bital Savir-Baruch, M.D (1) · Brittany Davidson, MD (1) · Ciro Gallo, M.D. (1) · Danielle Vicus, MD (1) · Daphne Gschwantler-Kaulich, Ass.Prof.Dr. (1) · Esther Broekman, MD (1) · Federica Tomao (1) · Francesco Perrone, M.D., Ph.D. (1) · Gennaro Daniele, M.D., Ph.D. (1) · Gini Fleming, MD (1)
PMID 18165618, PMID 19383827, PMID 20118030, PMID 26947961, PMID 31216198, PMID 31586247, PMID 33931498, PMID 34462317, PMID 39415516, PMID 39673810, PMID 41709925, PMID 42575837, PMID 42851761
2018 (1)